FDAnews
www.fdanews.com/articles/210171-fda-approves-genesis-medtechs-chocolate-touch-angioplasty-catheter

FDA Approves Genesis MedTech’s Chocolate Touch Angioplasty Catheter

November 15, 2022

The FDA granted approval to Genesis MedTech’s Chocolate Touch drug-coated balloon  catheter, an alternative to traditional drug-coated balloon angioplasty for peripheral artery disease.

The percutaneous transluminal angioplasty device is coated with paclitaxel, typically used as an anticancer drug, and is designed to open in small sections using coated pillow-like structures.

Genesis MedTech acquired the Chocolate Touch drug-coated balloon from TriReme Medical in August 2020, gaining the worldwide rights for use in the treatment, prevention, diagnosis or management of peripheral vascular diseases.

Genesis MedTech is planning to launch the product in the U.S. through its subsidiary, G Vascular.

View today's stories